JP5378379B2 - 癌の治療用の薬剤における活性成分としてのピペル・クベバ（ＰｉｐｅｒｃｕｂｅｂａＬ．）由来の抽出物または抽出物化合物の使用 - Google Patents
癌の治療用の薬剤における活性成分としてのピペル・クベバ（ＰｉｐｅｒｃｕｂｅｂａＬ．）由来の抽出物または抽出物化合物の使用 Download PDFInfo
- Publication number
- JP5378379B2 JP5378379B2 JP2010520393A JP2010520393A JP5378379B2 JP 5378379 B2 JP5378379 B2 JP 5378379B2 JP 2010520393 A JP2010520393 A JP 2010520393A JP 2010520393 A JP2010520393 A JP 2010520393A JP 5378379 B2 JP5378379 B2 JP 5378379B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- cancer
- alcohol
- fruit
- manufacturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 124
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 4
- 201000011510 cancer Diseases 0.000 title claims abstract description 4
- 239000004480 active ingredient Substances 0.000 title claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 239000001086 piper cubeba l. Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- XUEHVOLRMXNRKQ-KHMAMNHCSA-N alpha cubebene Natural products CC(C)[C@@H]([C@H]12)CC[C@@H](C)[C@]32[C@@H]1C(C)=CC3 XUEHVOLRMXNRKQ-KHMAMNHCSA-N 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 239000000341 volatile oil Substances 0.000 claims description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 230000002280 anti-androgenic effect Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 6
- 229960003473 androstanolone Drugs 0.000 claims description 6
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 4
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- 235000011869 dried fruits Nutrition 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 239000012752 auxiliary agent Substances 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 240000003731 Piper cubeba Species 0.000 claims 2
- 235000002711 Piper cubeba Nutrition 0.000 claims 2
- XUEHVOLRMXNRKQ-HKGGGCDWSA-N cubebene Chemical compound CC(C)[C@H]([C@@H]12)CC[C@H](C)C32C1C(C)=CC3 XUEHVOLRMXNRKQ-HKGGGCDWSA-N 0.000 claims 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 42
- 239000000126 substance Substances 0.000 description 23
- DIYWRNLYKJKHAM-MDOVXXIYSA-N (-)-cubebin Chemical compound C1=C2OCOC2=CC(C[C@@H]2[C@@H](CC=3C=C4OCOC4=CC=3)CO[C@@H]2O)=C1 DIYWRNLYKJKHAM-MDOVXXIYSA-N 0.000 description 21
- 230000006820 DNA synthesis Effects 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 15
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100032187 Androgen receptor Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010080146 androgen receptors Proteins 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 2
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000012432 gingerbread Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003693 proliferative and anti-apoptotic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940095585 testosterone-5-alpha reductase inhibitors for benign prostatic hypertrophy Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1289/07 | 2007-08-16 | ||
| CH01289/07A CH698627B1 (de) | 2007-08-16 | 2007-08-16 | Herstellung und Verwendung von Extrakten oder Extraktivstoffen aus Piper cubeba L. als wirksame Bestandteile in einem Medikament zur Behandlung von Krebserkrankungen. |
| PCT/CH2008/000350 WO2009021347A1 (de) | 2007-08-16 | 2008-08-15 | Verwendung von extrakten oder extraktivstoffen aus piper cubeba l. als wirksame bestandteile in einem medikament zur behandlung von krebserkrankungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536718A JP2010536718A (ja) | 2010-12-02 |
| JP2010536718A5 JP2010536718A5 (enExample) | 2011-09-29 |
| JP5378379B2 true JP5378379B2 (ja) | 2013-12-25 |
Family
ID=38668948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520393A Expired - Fee Related JP5378379B2 (ja) | 2007-08-16 | 2008-08-15 | 癌の治療用の薬剤における活性成分としてのピペル・クベバ（ＰｉｐｅｒｃｕｂｅｂａＬ．）由来の抽出物または抽出物化合物の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8404286B2 (enExample) |
| EP (1) | EP2182966B1 (enExample) |
| JP (1) | JP5378379B2 (enExample) |
| KR (1) | KR20100089815A (enExample) |
| CN (1) | CN102065875B (enExample) |
| AU (1) | AU2008286636B2 (enExample) |
| BR (1) | BRPI0815188A2 (enExample) |
| CA (1) | CA2696499A1 (enExample) |
| CH (1) | CH698627B1 (enExample) |
| ES (1) | ES2392310T3 (enExample) |
| PL (1) | PL2182966T3 (enExample) |
| RU (1) | RU2470657C2 (enExample) |
| WO (1) | WO2009021347A1 (enExample) |
| ZA (1) | ZA201000959B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472333B (zh) * | 2008-06-26 | 2015-02-11 | Piramal Entpr Ltd | 治療口腔念珠菌病之口服草本組成物 |
| JP5806231B2 (ja) * | 2009-12-21 | 2015-11-10 | アセフ エス．アー． | 勃起障害の治療における血管拡張剤としてのクベビン、ジベンジルブチルロラクトリンリグナン、その半合成誘導体および合成誘導体、ならびに他のリグナンおよびネオリグナン |
| WO2014027857A1 (ko) * | 2012-08-16 | 2014-02-20 | 부산대학교 산학협력단 | 알파-이소-쿠베벤 또는 알파-이소-쿠베베놀을 유효성분으로 포함하는 감염성 및 염증성 질환의 예방 또는 치료용 조성물 |
| WO2014086379A1 (en) | 2012-12-03 | 2014-06-12 | Alpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag | Lignan compositions |
| FR3085846B1 (fr) * | 2018-09-13 | 2022-01-21 | Robertet Sa | Utilisation d’extrait de p.nigrum, p. cubeba et/ou s. therebentifolius dans des preparations cosmetiques pour favoriser la pousse des poils |
| JP7197908B2 (ja) * | 2019-03-04 | 2022-12-28 | 株式会社ナチュファルマ琉球 | 骨減少性疾患の予防及び／又は治療用組成物 |
| CN114574286B (zh) * | 2022-02-18 | 2024-03-22 | 中国热带农业科学院香料饮料研究所 | 一种具有抗炎活性的胡椒精油及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815177D0 (en) * | 1998-07-13 | 1998-09-09 | King S College London | Treatment of skin disorders |
| JP3091962B2 (ja) * | 1998-09-25 | 2000-09-25 | アルプス薬品工業株式会社 | テストステロン−５α−レダクターゼ阻害剤 |
| WO2003047551A1 (en) * | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| BR0201237A (pt) | 2002-03-25 | 2003-12-02 | Fundacao De Amparo A Pesquisa | Processo de obtenção de lignanas dibenzilbutirolactÈnicas, processo de obtenção de derivados sintéticos de lignanas ostentando atividades quimioprofilática e terapêutica antichagásica |
| US20030228383A1 (en) * | 2002-06-06 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals, Ltd. | Herbal cough formulations and process for the preparation thereof |
| JP2004160165A (ja) * | 2002-09-17 | 2004-06-10 | Pauretsuku:Kk | 生薬成分製剤の造粒方法 |
| EP1581237B1 (en) * | 2002-12-30 | 2007-06-27 | Council of Scientific and Industrial Research | Development of an anti-cough, anti-tussive and throat soothing herbal formulation |
| JP4319417B2 (ja) * | 2003-01-30 | 2009-08-26 | 学校法人近畿大学 | メラニン産生不全症治療剤 |
| US20070248693A1 (en) * | 2003-08-02 | 2007-10-25 | Elizabeth Mazzio | Nutraceutical composition and method of use for treatment / prevention of cancer |
-
2007
- 2007-08-16 CH CH01289/07A patent/CH698627B1/de not_active IP Right Cessation
-
2008
- 2008-08-15 JP JP2010520393A patent/JP5378379B2/ja not_active Expired - Fee Related
- 2008-08-15 CN CN200880111798XA patent/CN102065875B/zh not_active Expired - Fee Related
- 2008-08-15 PL PL08783450T patent/PL2182966T3/pl unknown
- 2008-08-15 AU AU2008286636A patent/AU2008286636B2/en not_active Ceased
- 2008-08-15 WO PCT/CH2008/000350 patent/WO2009021347A1/de not_active Ceased
- 2008-08-15 CA CA2696499A patent/CA2696499A1/en not_active Abandoned
- 2008-08-15 US US12/673,656 patent/US8404286B2/en not_active Expired - Fee Related
- 2008-08-15 ES ES08783450T patent/ES2392310T3/es active Active
- 2008-08-15 KR KR1020107005684A patent/KR20100089815A/ko not_active Ceased
- 2008-08-15 RU RU2010109750/15A patent/RU2470657C2/ru not_active IP Right Cessation
- 2008-08-15 BR BRPI0815188 patent/BRPI0815188A2/pt not_active IP Right Cessation
- 2008-08-15 EP EP08783450A patent/EP2182966B1/de active Active
-
2010
- 2010-02-10 ZA ZA201000959A patent/ZA201000959B/xx unknown
-
2013
- 2013-02-28 US US13/780,129 patent/US9248156B2/en not_active Expired - Fee Related
-
2016
- 2016-02-02 US US15/013,654 patent/US20160193272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100089815A (ko) | 2010-08-12 |
| EP2182966B1 (de) | 2012-08-08 |
| AU2008286636A1 (en) | 2009-02-19 |
| RU2470657C2 (ru) | 2012-12-27 |
| WO2009021347A1 (de) | 2009-02-19 |
| AU2008286636B2 (en) | 2013-10-24 |
| US20110135760A1 (en) | 2011-06-09 |
| CH698627B1 (de) | 2009-09-15 |
| ZA201000959B (en) | 2010-10-27 |
| CN102065875B (zh) | 2013-07-17 |
| RU2010109750A (ru) | 2011-09-27 |
| US9248156B2 (en) | 2016-02-02 |
| BRPI0815188A2 (pt) | 2015-03-31 |
| US20160193272A1 (en) | 2016-07-07 |
| CN102065875A (zh) | 2011-05-18 |
| PL2182966T3 (pl) | 2013-01-31 |
| CA2696499A1 (en) | 2009-02-19 |
| US20130251826A1 (en) | 2013-09-26 |
| ES2392310T3 (es) | 2012-12-07 |
| US8404286B2 (en) | 2013-03-26 |
| JP2010536718A (ja) | 2010-12-02 |
| EP2182966A1 (de) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5378379B2 (ja) | 癌の治療用の薬剤における活性成分としてのピペル・クベバ（ＰｉｐｅｒｃｕｂｅｂａＬ．）由来の抽出物または抽出物化合物の使用 | |
| Roy et al. | Evaluation of in vitro cytotoxic and antioxidant activity of Datura metel Linn. and Cynodon dactylon Linn. extracts | |
| KR20060109893A (ko) | 잔토세라스 소르비폴리아 추출물을 포함하는 조성물,이로부터 단리된 화합물, 이의 제조방법 및 이의 용도 | |
| Zhang et al. | Antioxidant and anti-proliferative activity of Rhizoma Smilacis Chinae extracts and main constituents | |
| Saddi et al. | Prophylactic mechanisms of Cucumis melo var. flexuosus and Phoenix dactylifera fruit extracts against diabetic cardiomyopathy in streptozotocin induced diabetic rats. | |
| Eberle et al. | Optimization of extraction methods for total polyphenolic compounds obtained from rhizomes of Zingiber officinale | |
| Elazzouzi et al. | Total phenolic and flavonoid contents of Anacyclus pyrethrum Link plant extracts and their Antioxidant activity | |
| Etta et al. | Effect of Irvingia gabonensis (Aubry-Lecomte ex O’Rorke) seeds on the liver and gonads of male albino rats | |
| Prakash et al. | Bioactive extracts of Ziziphus mauritiana induces apoptosis in A549 human lung epithelial carcinoma cells through the generation of reactive oxygen species | |
| Rini et al. | Impact of geographical location on the polyphenolic content of Nigella sativa seed extract and the relative anti-inflammatory and antioxidant potential thereof: A comparative study | |
| Sayed et al. | In Vitro antiproliferative potential of essential oil extract from Carica papaya L. seeds against cervical cancer | |
| Shaikh et al. | Centella Asiatica, a Potent Herbal Anticancer Agent | |
| Triyono et al. | Antioxidant Activity of Ethanol Extract of Turmeric Rhizome (Curcuma domestica Val), Trengguli Bark (Cassia fistula L), and Its Combination with DPPH Method | |
| Salem et al. | ANTI-CANCER ACTIVITY OF GRAVIOLA (Annona muricata) LEAVES EXTRACT ON INDUCED BREAST CANCER IN RATS’MODEL. | |
| Perez et al. | Antioxidant, neuroprotective and anti-inflammatory activity of Curcuma longa extracts: from green extraction to nanoemulsion | |
| Arundina et al. | Effects of Nanoparticle of Saussurea lappa on Stem Cell from Human Exfoliated Deciduous Teeth (SHED) Proliferation and Cancer Cell Inhibition. | |
| Maurya et al. | Antiproliferative Effects of Methanolic Fruit Extract of Solanum xenthocarpum (L.) on Human Breast Cancer Cells | |
| Thi et al. | The Comparison of Antioxidative and Cytotoxic Activities of Fresh and Dried Piper betle L. leave Extracts on MCF-7, HELA and SK-LU-1 | |
| Malyarenko et al. | Brown alga Costaria costata as a source of phlorethol that inhibits TPA-induced neoplastic cell transformation and progression of human breast cancer cells via AKT/GSK-3β/CDKs pathway | |
| Shaker et al. | Evaluation of the chemical content of the leaf extract of Physalis angulate L. extracted using GC–MS and its effect on the wound healing process | |
| Gupta et al. | Assessment of In Vitro Antioxidant Efficacy and Phytochemical Profiling in Different Solvent Extracts of Cannonball tree (Couroupita guianensis Aubl.). | |
| BENBACER et al. | Unlocking the antiproliferative properties of Anacyclus pyrethrum: A tribute to Moroccan traditional healing | |
| Gupta et al. | In-vitro Antioxidant Activity of Aqueous Extract of Physalis minima Linn. | |
| Salhi et al. | Antioxidant, anti-inflammatory, and antiproliferative activities of aqueous extract from Calamintha nepeta L. leaves | |
| Rusdiana et al. | Tropical Journal of Natural Product Research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110810 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130731 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130917 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130925 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |